Cardiometabolic comorbidity in antipsychotic treated patients: Need for systematic evaluation and treatment

International Journal of Psychiatry in Clinical Practice

Volumn 17, Issue 2, 2013, Pages 125-130

  Steylen, Pauline M J ^a   Van Der Heijden, Frank M M A ^a   Kok, Hans D H ^a   Sijben, No A E S ^b   Verhoeven, Willem M A ^a,c  

^a VINCENT VAN GOGH INSTITUTE FOR PSYCHIATRY   (Netherlands)

^b ABC/OPES Consultancies   (Netherlands)

^c ERASMUS MEDICAL CENTER   (Netherlands)

Author keywords

Antipsychotics; Cardiometabolic risk factors; Severe mental illness; Somatic treatment

Indexed keywords

ANGIOTENSIN 2 RECEPTOR ANTAGONIST; ANTIDEPRESSANT AGENT; ANTIHYPERTENSIVE AGENT; ATORVASTATIN; BENZODIAZEPINE; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; BEZAFIBRATE; CALCIUM ANTAGONIST; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; FIBRIC ACID DERIVATIVE; FLUINDOSTATIN; HIGH DENSITY LIPOPROTEIN; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; INSULIN; METFORMIN; MOOD STABILIZER; NEUROLEPTIC AGENT; ORAL ANTIDIABETIC AGENT; PRAVASTATIN; ROSUVASTATIN; SIMVASTATIN; TRIACYLGLYCEROL;

ADULT; ARTICLE; BIPOLAR DISORDER; CARDIOMETABOLIC RISK; COMORBIDITY; DEPRESSION; DIABETES MELLITUS; FEMALE; HUMAN; HYPERCHOLESTEROLEMIA; HYPERTENSION; MAJOR CLINICAL STUDY; MALE; MENTAL PATIENT; METABOLIC SYNDROME X; OBESITY; PATIENT PARTICIPATION; PREVALENCE; PRIORITY JOURNAL; PSYCHOSIS; SCHIZOAFFECTIVE PSYCHOSIS; SCHIZOPHRENIA; SEX DIFFERENCE;

ADOLESCENT; ADULT; AGE FACTORS; ANTIPSYCHOTIC AGENTS; CARDIOVASCULAR DISEASES; COHORT STUDIES; COMORBIDITY; DIABETES MELLITUS; FEMALE; HUMANS; HYPERCHOLESTEROLEMIA; HYPERTENSION; MALE; MENTAL DISORDERS; METABOLIC SYNDROME X; NETHERLANDS; PREVALENCE; PSYCHOTROPIC DRUGS; RISK FACTORS;

EID: 84877938092     PISSN: 13651501     EISSN: 14711788     Source Type: Journal    
DOI: 10.3109/13651501.2013.779000     Document Type: Article

References (46)

1. Baker WL, Talati R, White CM, Coleman CI. 2010. Diff ering eff ect of statins on insulin sensitivity in non-diabetics: a systematic review and meta-analysis. Diabetes Res Clin Pract 87: 98-107.
2. Baptista T, Kin NM, Beaulieu S. 2004. Treatment of the metabolic disturbances caused by antipsychotic drugs: focus on potential drug interactions. Clin Pharmacokinet 43: 1-15.
3. Brown S. 1997. Excess mortality of schizophrenia: a meta-analysis. Br J Psychiatry 171: 502-508.
4. Colton CW, Manderscheid RW. 2006. Congruencies in increased mortality rates, years of potentiallife lost, and causes of death among public mental health clients in eight states. Prev Chronic Dis 3: 1-14.
5. De Hert M, Cohen D, Bobes J, Cetkovich-Bakmas M, Leucht S, Ndetei DM, et al. 2011. Physical illness in patients with severe mental disorders. II. Barriers to care, monitoring and treatment guidelines, plus recommendations at the system and individuallevel. World Psychiatry 10: 138-151.
6. De Hert M, Correll CU, Bobes J, Cetkovich-Bakmas M, Cohen D, Asai I, et al. 2011. Physical illness in patients with severe mental disorders. I. Prevalence, impact of medications and disparities in health care. World Psychiatry 10: 52-77.
7. De Hert M, Dekker JM, Wood D, Kahl KG, Holt RI, Möller HJ. 2009. Cardiovascular disease and diabetes in people with severe mental illness position statement from the European Psychiatric Association (EPA), supported by the European Association for the Study of Diabetes (EASD) and the European Society of Cardiology (ESC). Eur Psychiatry 24: 412-424.
8. Elliot W, Meyer PM. 2007. Incident diabetes in clinical trials of antihypertensive drugs: a network meta-analysis. Lancet 369: 201-207.
9. Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults. 2001. Executive Summary of the Th ird Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) (2001). JAMA 285: 2486-2497.
10. Graham I, Atar D, Borch-Johnsen K, Boysen G, Burell G, Cifk ova R, et al. 2007. European guidelines on cardiovascular disease prevention in clinical practice: executive summary: Fourth Joint Task Force of the European Society of Cardiology and Other Societies on Cardiovascular Disease Prevention in Clinical Practice. Eur Heart J 28: 2375-2414.
11. Gupta K, Gupta S. 2002. Undertreatment of hypertension: a dozen reasons. Arch Intern Med 162: 2246-2247.
12. Haff ner SM, Stern MP, Hazuda HP, Mitchell BD, Patterson JK. 1990. Cardiovascular risk factors in confirmed prediabetic inidividuals. JAMA 263: 2893-2898.
13. Heila H, Haukka J, Suvisaari J, Lönnqvist J. 2005. Mortality among patients with schizophrenia and reduced psychiatric hospital care. Psychol Med 35: 725-732.
14. Hennekens CH, Hennekens AR, Hollar D, Casey DE. 2005. Schizophrenia and increased risk of cardiovascular disease. Am Heart J 150: 1115-1121.
15. Killbourne AM, Welsh D, McCarthy JF, Post EP, Blow FC. 2008. Quality of care for cardiovascular disease-related conditions in patients with and without mental disorders. J Gen Intern Med 23: 1628-1633.
16. Koh KK, Sakuma I, Quon MJ. 2011. Diff erential metabolic eff ects of distinct statins. Atherosclerosis 215: 1-8.
17. Laursen TM. 2011. Life expectancy among persons with schizophrenia or bipolar aff ective disorder. Schizoprh Res 131: 101-104.
18. Laursen TM, Munk-Olsen T, Vestergaard M. 2012. Life expectancy and cardiovascular mortality in persons with schizophrenia. Curr Opin Psychiatry 25: 83-88.
19. Lawrence D, Kisely S, Pais J. 2010. The epidemiology of excess mortality in people with mental illness. Can J Psychiatry 55: 752-760.
20. L'Italien GJ, Casey DE, Kan HJ, Carson WH, Marcus RN. 2007. Comparison of metabolic syndrome incidence among schizophrenia patients treated with aripiprazole versus olanzapine or placebo. J Clin Psychiatry 68: 1510-1516.
21. Mitchell AJ, Delaffon V, Vancampfort D, Correll CU, De Hert M. 2012. Guideline concordant monitoring of metabolic risk in people treated with antipsychotic medication: systematic review and meta-analysis of screening practices. Psychol Med 42: 125-147.
22. Mitchell AJ, Vancampfort D, Sweers K, van Winkel R, Yu W, De Hert M. 2011. Prevalance of metabolic syndrome and metabolic abnormalities in schizophrenia and related disorders. Asystematic review and meta-analysis. Schizophr Bull. Epub ahead of print 29 December 2011; doi:10.1093/schbul/sbr148.
23. Nasrallah HA, Meyer JM, Goff DC, McEvoy JP, Davis SM, Stroup TS, Lieberman JA. 2006. Low rates of treatment for hypertension, dyslipidemia and diabetes in schizophrenia: data from the CATIE schizophrenia trial sample at baseline. Schizophr Res 86: 15-22.
24. Ösby U, Correia N, Brandt L, Ekbom A, Sparén P. 2000. Mortality and causes of death in schizophrenia in Stockholm County, Sweden. Schizophr Res 45: 21-28.
25. Pearson TA. 2000. The undertreatment of LDL-cholesterol: addressing the challenge. Int J Cardiol 74: S23-S28.
26. Rydén L, Standl E, Bartnik M, Van den Berghe G, Betteridge J, de Boer MJ, et al. 2007. Guidelines on diabetes, pre-diabetes, and cardiovascular diseases: executive summary. The Task Force on Diabetes and Cardiovascular Diseases of the European Society of Cardiology (ESC) and of the European Association for the Study of Diabetes (EASD). Eur Heart J 28: 88-136.
27. Saarni SE, Saarni SI, Fogelholm M, Heli övaara M, PeralaJ, Suvisaari J, Lönnqvist J. 2009. Body composition in psychotic disorders: a general population survey. Psychol Med 39: 801-810.
28. Saddichha S, Manjunatha N, Ameen S, Akhtar S. 2008. Diabetes and schizophrenia-eff ect of disease or drug? Results from a randomized double-blind, controlled prospective study in first-episode schizophrenia. Acta Psychiatr Scand 117: 342-347.
29. Schorr SG, Slooff CJ, Burggeman R, Taxis K. 2009. The incidence of metabolic syndrome and its reversal in a cohort of schizophrenic patients followed for one year. J Psychiatr Res 43: 1106-1111.
30. Scott D, Happell B. 2011. The high prevalence of poor physical health and unhealthy lifestyle behaviours in individuals with severe mental illness. Issues Ment Helath Nurs 32: 589-597.
31. Sharma AM, Pischon T, Hardt S, Kunz I, Luft FC. 2001. Hypothesis: -adrenergic receptor blockers and weight gain: a systematic analysis. Hypertension 37: 250-254.
32. Srisurapanont M, Likhitsathian S, Boonyanaruthee V, Charnsilp C, Jarusaraisin N. 2007. Metabolic syndrome in Th ai schizophrenic patients: a naturalistic one-year follow-up study. BMC Psychiatry 7: 14-19.
33. Stahl SM, Mignon L, Meyer JM. 2009. Which comes first: atypical antipsychotic treatment of cardiometabolic risk? Acta Psychiatr Scand 119: 171-179.
34. Taxis K, Schorr S, Fouchier M, Slooff C, Bruggeman R. 2008. Is it appropriate to use cardiovascular risk scores in patients with psychotic disorders? Schizophr Res 102: 169.
35. Taylor F, Ward K, Moore THM, Burke M, Davey Smith G, Casas JP, et al. 2011. Statins for the primary prevention of cardiovascular disease (Review). Cochrane Database Syst Rev 19: CD004816.
36. Tiihonen J, Lönnqvist J, Wahlbeck K, Kalukka T, Niskanen L, Tanskanen A, Haukka J. 2009. 11-year follow-up of mortality in patients with schizophrenia: a population-based cohort study (FIN11study). Lancet 374: 620-627.
37. Tonstad S, Rosvold EO, Furu K, Skurtveit S. 2004. Undertreatment and overtreatment with statins: the Oslo Health Study 2000-2001. J Intern Med 255: 494-502.
38. Vancampfort D, Knapen J, Probst M, Winkel R, Deckx S, Maurissen K, et al. 2010. Considering a frame of reference for physical activity research related to the cardiometabolic risk profile in schizophrenia. Psychiatry Res 177: 271-279.
39. Van Der Gaag RJ. 2011. Mental health 'cure and care'in the Netherlands: risks and opportunities. Int Rev Psychiatry 23: 113-117.
40. Van Hout BA, Simoons ML. 2001. Cost-eff ectiveness of HMG coenzyme reductase inhibitors. Whom to treat? Eur Heart J 22: 751-761.
41. Verhaeghe N, De Maeseneer J, Maes L, Van Heeringen C, Annemans L. 2011. Eff ectiveness and cost-eff ectiveness of life-style interventions on physical activity and eating habits in persons with severe mental disorders: a systematic review. Int J Behav Nutr Phys Act 8: 28-39.
42. Vreeland B. 2007. Treatment decisions in major mental illness: weighing the outcomes. J Clin Psychiatry 68: 5-11.
43. Ward S, Lloyd Jones M, Pandor A, Holmes M, Ara R, Ryan A, et al. 2007. Asystematic review and economic evaluation of statins for the prevention of coronary events. Health Technol Assess 11: 1-160.
44. Webber MA, Mahmud W, Lightfoot JD, Shekhar A. 2004. Rhabdomyolysis and compartment syndrome with coadministration of risperidone and simvastatin. J Psychopharmacol 18: 432-434.
45. Weiss AP, Henderson DC, Weilburg JG, Goff DC, Meigs JB, Cagliero E, Grant RW. 2006. Treatment of cardiac risk factors among patients with schizophrenia and diabetes. Psychiatr Serv 57: 1145-1152.
46. Winer N, Sowers JR. 2004. Epidemiology of diabetes. J Clin Pharmacol 44: 397-405.